id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-P-7033-0007,FDA,FDA-2017-P-7033,Response Letter from FDA CDER to Jubilant Generics Limited,Other,Approval,2023-04-19T04:00:00Z,2023,4,2023-04-19T04:00:00Z,,2023-04-19T20:15:12Z,,0,0,090000648595eec0